Drug Sponsors

Lundbeck, CHDI Foundation collaborate on Huntington’s disease

Tuesday, May 22, 2012 10:23 AM

Lundbeck, a pharmaceutical company based in Deerfield, Ill. and CHDI Foundation, a not-for-profit biomedical research organization, have formed a research collaboration to investigate a targeted therapy for Huntington’s disease.

More... »


Wellcome Trust awards Phagenesis $1.5 million for dysphagia treatment

Tuesday, May 22, 2012 10:02 AM

Phagenesis, a U.K. company focused on dysphagia (the inability to swallow), has been awarded $1.5 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community.

More... »


GE Healthcare and Karolinska University to advance cell therapy

Tuesday, May 22, 2012 09:38 AM

Karolinska University Hospital Sweden, one of Europe's largest teaching hospitals, and GE Healthcare Life Sciences have formed a research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy.

More... »

Provence and Neuroptis collaborate on dry eye syndrome

Monday, May 21, 2012 01:03 PM

French companies Provence Technologies, a service provider of specialist fine chemistry, and Neuroptis Biotech, specializing in the discovery and development of innovative therapies in neurology and ophthalmology, are strengthening of their collaboration for transferring the chemical development of Neuroptis Biotech’s drug candidate ML7 and producing the first GMP batches before the end of 2012.

More... »

Auxilium and GSK to co-promote Testim in U.S.

Monday, May 21, 2012 12:35 PM

Auxilium Pharmaceuticals, a specialty biopharmaceutical company based in Malvern, Penn., and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc, have entered into an agreement for the co-promotion of Auxilium’s Testim 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone.

More... »

Nitto Denko acquires all assets of Altea Therapeutics

Thursday, May 17, 2012 09:39 AM

Nitto Denko, a Japanese materials manufacturer, has acquired all the assets of Altea Therapeutics, a creator of transdermal drug delivery systems.

More... »

GlaxoSmithKline to fully acquire Cellzome for $97.2 million

Wednesday, May 16, 2012 10:47 AM

GlaxoSmithKline has entered into an agreement with Cellzome, a privately-held chemical proteomics company, to acquire all shares in the company it does not currently own for $99 million in cash. Cellzome, which has laboratories in Cambridge, U.K., and Heidelberg, Germany, will become part of GSK's R&D organization.

More... »

Zambon collaborates with Newron, licenses Parkinson’s treatment

Wednesday, May 16, 2012 10:25 AM

Zambon, an Italian chemical and pharmaceutical company, has formed a strategic collaboration and license agreement with Newron Pharmaceuticals, an R&D company focused on novel CNS and pain therapies, for the latter’s lead compound safinamide.

More... »

Promedior names Suzanne L. Bruhn president and CEO

Wednesday, May 16, 2012 10:08 AM

Promedior, a Malvern, Penn.-based clinical stage biotech developing novel biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn, Ph.D., as president, CEO and to the board of directors.

More... »

BMS and Tsinghua University form strategic partnership

Wednesday, May 16, 2012 09:57 AM

Bristol-Myers Squibb and Tsinghua University of Beijing have entered into a multi-year strategic partnership.

More... »

`

CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs